Plasma Restoration of Endothelial Glycocalyx in a Rodent Model of Hemorrhagic Shock

Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Anesthesia and analgesia (Impact Factor: 3.42). 02/2011; 112(6):1289-95. DOI: 10.1213/ANE.0b013e318210385c
Source: PubMed

ABSTRACT The use of plasma-based resuscitation for trauma patients in hemorrhagic shock has been associated with a decrease in mortality. Although some have proposed a beneficial effect through replacement of coagulation proteins, the putative mechanisms of protection afforded by plasma are unknown. We have previously shown in a cell culture model that plasma decreases endothelial cell permeability in comparison with crystalloid. The endothelial glycocalyx consists of proteoglycans and glycoproteins attached to a syndecan backbone, which together protect the underlying endothelium. We hypothesize that endothelial cell protection by plasma is due, in part, to its restoration of the endothelial glycocalyx and preservation of syndecan-1 after hemorrhagic shock.
Rats were subjected to hemorrhagic shock to a mean arterial blood pressure of 30 mm Hg for 90 minutes followed by resuscitation with either lactated Ringer's (LR) solution or fresh plasma to a mean arterial blood pressure of 80 mm Hg and compared with shams or shock alone. After 2 hours, lungs were harvested for syndecan mRNA, immunostained with antisyndecan-1, or stained with hematoxylin and eosin. To specifically examine the effect of plasma on the endothelium, we infused small bowel mesentery with a lanthanum-based solution, identified venules, and visualized the glycocalyx by electron microscopy. All data are presented as mean ± SEM. Results were analyzed by 1-way analysis of variance with Tukey post hoc tests.
Electron microscopy revealed degradation of the glycocalyx after hemorrhagic shock, which was partially restored by plasma but not LR. Pulmonary syndecan-1 mRNA expression was higher in animals resuscitated with plasma (2.76 ± 0.03) in comparison with shock alone (1.39 ± 0.22) or LR (0.82 ± 0.03) and correlated with cell surface syndecan-1 immunostaining. Shock also resulted in significant lung injury by histopathology scoring (1.63 ± 0.26), which was mitigated by resuscitation with plasma (0.67 ± 0.17) but not LR (2.0 ± 0.25).
The protective effects of plasma may be due in part to its ability to restore the endothelial glycocalyx and preserve syndecan-1 after hemorrhagic shock.

  • Source
    • "Shock-mediated injury of the vascular endothelium has been examined as a mechanism of TAC. This injury also includes disruption of the covering glycocalyx throughout the vascular space [60] [61] [62] [63] [64]. Negatively charged proteoglycans, glycoproteins, and glycolipids, including significant amounts of heparin-like molecules [65,66] of the glycocalyx have a dynamic role in a number of endothelial cell functions [67]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The early recognition and management of hemorrhage shock are among the most difficult tasks challenging the clinician during primary assessment of the acutely bleeding patient. Often with little time, within a chaotic setting, and without sufficient clinical data, a decision must be reached to begin transfusion of blood components in massive amounts. The practice of massive transfusion has advanced considerably and is now a more complete and, arguably, more effective process. This new therapeutic paradigm, referred to as damage control resuscitation (DCR), differs considerably in many important respects from previous management strategies for catastrophic blood loss. We review several important elements of DCR including immediate correction of specific coagulopathies induced by hemorrhage and management of several extreme homeostatic imbalances that may appear in the aftermath of resuscitation. We also emphasize that the foremost objective in managing exsanguinating hemorrhage is always expedient and definitive control of the source of bleeding. Copyright © 2015. Published by Elsevier Ltd.
    Blood Reviews 01/2015; 46. DOI:10.1016/j.blre.2014.12.006 · 5.45 Impact Factor
  • Anesthesia and analgesia 06/2011; 112(6):1272-3. DOI:10.1213/ANE.0b013e318217f816 · 3.42 Impact Factor
  • Annals of surgery 06/2011; 254(2):201-2. DOI:10.1097/SLA.0b013e318226483d · 7.19 Impact Factor
Show more